Alzamend Neuro Inc - ALZN STOCK NEWS

IMPACT

SENTIMENT

11/20/2023 08:00 AM

ALZN : Nasdaq

Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients

IMPACT

SENTIMENT

11/16/2023 08:00 AM

ALZN : Nasdaq

Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

IMPACT

SENTIMENT

11/13/2023 08:00 AM

ALZN : Nasdaq

Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001

IMPACT

SENTIMENT

10/30/2023 08:00 AM

ALZN : Nasdaq

Alzamend Neuro Announces Reverse Stock Split

IMPACT

SENTIMENT

10/23/2023 08:00 AM

ALZN : Nasdaq

Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001

IMPACT

SENTIMENT

10/02/2023 08:00 AM

ALZN : Nasdaq

Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients

IMPACT

SENTIMENT

09/22/2023 08:00 AM

ALZN : Nasdaq

Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement

IMPACT

SENTIMENT

08/30/2023 08:00 AM

ALZN : Nasdaq

Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients

IMPACT

SENTIMENT

06/22/2023 08:00 AM

ALZN : Nasdaq

Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001

IMPACT

SENTIMENT

04/04/2023 06:30 AM

AULT : AMEX ALZN : Nasdaq

Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type

Alzamend Neuro Inc

Nasdaq:ALZN

ALZN Rankings

N/A Ranked by Market Cap

N/A Ranked by Dividends

ALZN Stock Data

Industry Pharmaceutical Preparation Manufacturing

Sector Manufacturing

Website Link

Country United States

City Tampa

About ALZN

alzamend neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of alzheimer’s disease, bipolar disorder, major depressive disorder (“mdd”) and post-traumatic stress disorder (“ptsd”). our mission is to rapidly develop and market safe and effective treatments to bring aid to the 43+ million americans suffering from these debilitating diseases. our current pipeline consists of two novel therapeutic drug candidates, al001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and alzn002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat alzheimer’s.